Posted by Michael Wonder on 06 Jul 2025
MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer
4 July 2025 - The MHRA has today approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may include tumours.
This medicine has been approved through the International Recognition Procedure (IRP). The IRP allows the MHRA to consider the expertise and decision-making of trusted regulatory partners for the benefit of UK patients.
